C-Met-IN-14
C-Met-IN-14 (compound 26af) is a selective inhibitor of c-Met kinase from N-sulfonylamidine-based derivatives, with an IC50 value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner[1].
Product Specifications
CAS Number
2443380-34-3
UNSPSC
12352005
Target
Apoptosis; c-Kit; c-Met/HGFR; FLT3
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/c-met-in-14.html
Solubility
10 mM in DMSO
Smiles
COCC/C(NC1=CC=C(OC2=CC=NC3=CC(OCCCN4CCOCC4)=C(OC)C=C23)C(F)=C1)=N/S(=O)(CC5=CC=C(Cl)C=C5)=O
Molecular Formula
C34H38ClFN4O7S
Molecular Weight
701.20
References & Citations
[1]Nan X, et al. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction. Eur J Med Chem. 2020 Aug 15. 200:112470.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401748-100 1x 100 µL
Ubiquitin (Autophagy Marker) (UBB/1748), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472745-500 1x 500 µL
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2745), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details